However, as the

antigen is non-toxic, it can be formulated at much higher concentrations and did stimulate much stronger responses when administered at 10-fold higher concentrations. Initial experiments used the model antigen (eGFP) but we believe that this strategy of vaccination could be applied to a whole variety of viral, bacterial and parasitic antigens. To confirm the relevance of this approach, animals were immunised with the recombinant fusions protein PsaAPLY and PsaAΔ6PLY. Whilst the study undertaken confirmed the utility of the approach to generate high levels of antigen specific antibody, this appeared insufficient to protect the animals against local or systemic infection against several strains of S. pneumoniae. The relatively low level of efficacy was unexpected, (given that PsaA has been identified as a putative vaccine candidate [25]), Pictilisib purchase but the poor level of protection observed may reflect the choice of the antigen rather than the success of vaccination. PsaA is a surface located protein found on the pneumococcus, which has been shown to display varying levels of protection Quizartinib research buy in animal models [26]. With this antigen, the level of encapsulation in vivo

is highly relevant as high levels of capsule production can inhibit binding of antibody to the PsaA antigen. Thus it is possible that whilst high levels of antibody to PsaA may be present, the presence of a capsule in vivo may have significantly reduced the accessibility of the antigen to the antibody. We believe that vaccination using this antigenic formulation is exciting, despite these initial difficulties, for several reasons. Firstly, the relative ease of Etomidate insertion of new antigens to make fusions. Secondly, the purification procedure is relatively simple allowing

this technology to form the basis of a generic vaccine platform to which many different antigens could be rapidly applied. In addition, the availability of non-haemolytic mutants of the toxins that can be given in greater concentrations to generate the same levels of activity as the native toxin. This is very attractive, as this avoids complications associated with use of the haemolytic form of the toxin. Interestingly, in contrast to LT, where strong responses are first generated to the toxin [27], responses to PLY are secondary to the response to the carried antigen. Also significant is the immunity generated to the PLY itself as this is likely to augment protection against disease [11]. In light of the success of this approach, further studies are planned to establish the importance of the structure of the pneumolysin in the generation of this strong mucosal response. The results from the non-haemolytic mutant eGFPΔ6PLY and PsaAΔ6PLY suggest that binding of the toxin to the membrane is required for adjuvanticity.